

Selected Innovative Medicines in Development as of October 15, 2024



Oncology (1 of 2)

RYBREVANT

Non Small Cell Lung Cancer 2L (MARIPOSA-2)

DARZALEX (daratumumab)

Frontline multiple myeloma transplant eligible (PERSEUS)

RYBREVANT (amivantamab)

Subcutaneous (PALOMA-3)

TECVAYLI (teclistamab)

Relapsed Refractory Multiple Myeloma CD38 exposed (MajesTEC-9)

TECVAYLI (teclistamab)

Multiple Myeloma 1-3PLs (MajesTEC-3)

TALVEY (talquetamab)

Relapsed Refractory Multiple Myeloma A-CD38 Naïve (MonumentAL-3)

TAR-200 (RIS/gemcitabine plus cetrelimab)

Non Muscle Invasive Bladder Cancer BCG-naïve High Risk (SunRISe-3)

ERLEADA (apalutamide)

Localized Prostate Cancer (ATLAS)

RYBREVANT / LAZCLUZE

Non Small Cell Lung Cancer (MARIPOSA)

DARZALEX (daratumumab)

Frontline multiple myeloma transplant ineligible (CEPHEUS)

RYBREVANT (amivantamab)

Frontline Non Small Cell Lung Cancer in combination with chemotherapy (PAPILLON)

TECVAYLI (teclistamab)

TIE NDMM in combination with DR (MajesTEC-7)

TAR-210 (RIS/erdafitinib)

Intravesical Delivery System for Localized Bladder Cancer (MoonRISe-1)

AKEEGA (niraparib/abiraterone)

M1 Metastatic Castration-Sensitive Prostate Cancer (AMPLITUDE)

DARZALEX (daratumumab)

Smoldering Multiple Myeloma (AQUILA)

CARVYKTI (Ciltacabtagene autoleucel)

Frontline Multiple Myeloma Transplant Eligible vs ASCT (CARTITUDE-6)

IMBRUVICA (ibrutinib)

Frontline Chronic Lymphocytic Leukemia (I + V fixed duration) (GLOW)

BALVERSA (erdafitinib)

Urothelial Cancer (THOR)

TALVEY (talquetamab)

TIE NDMM in combination with DR (MajesTEC-7)

TECVAYLI (teclistamab)

TE NDMM maintenance (MajesTEC-4)

TALVEY (talquetamab)

Relapsed Refractory Multiple Myeloma CD38 exposed (MonumentAL-6)

TAR-200

High Risk Non Muscle Invasive Bladder Cancer BGC Experienced (SunRISe-5)

ERLEADA (apalutamide)

High Risk Prostate Cancer (PROTEUS)

CARVYKTI (Ciltacabtagene autoleucel)

Frontline Multiple Myeloma TNI (CARTITUDE-5)

Oncology (2 of 2)

TAR-200 (RIS/gemcitabine plus cetrelimab)

Non Muscle Invasive Bladder Cancer (SunRISe-1)

JNJ-8177 (ARX517)

Prostate Cancer

JNJ-8377

Lymphoma

JNJ-1493

Hematological Malignancies

JNJ-5322

Multiple Myeloma

JNJ-6617

Hematological Malignancies

JNJ-0631 (ARX305)

Renal Cancer

JNJ-0683 (ARX788)

Breast Cancer

JNJ-4496

Hematological Malignancies

JNJ-9968

Hematological Malignancies

JNJ-9401

Prostate Cancer

JNJ-2421

Solid Tumor Targeted Therapy

JNJ-6420

Prostate Cancer

VAC85135

Hematological Malignancies

JNJ-9530

Hematological Malignancies

JNJ-0387

Solid Tumors

JNJ-8543

Hematological Malignancies

JNJ-8343

Prostate Cancer

JNJ-4681

Hematological Malignancies

Immunology (1 of 2)

TREMFYA (guselkumab)

Crohn's Disease Subcutaneous Induction (GRAVITI)

STELARA (ustekinumab)

Pediatric Juvenile Psoriatic Arthritis

TREMFYA (guselkumab)

Pediatric Juvenile Psoriatic Arthritis

TREMFYA (guselkumab)

Psoriatic Arthritis Structural Damage (APEX)

SIMPONI (golimumab)

Pediatric Ulcerative Colitis (PURSUIT 2)

JNJ-2113

Psoriasis (ICONIC)

nipocalimab

Systemic Lupus Erythematosus

JNJ-4804 Co-antibody Therapeutic

Psoriatic Arthritis

TREMFYA (guselkumab)

Ulcerative Colitis (QUASAR)

STELARA (ustekinumab)

Pediatric Crohn's Disease (UNITY JR)

TREMFYA (guselkumab)

Pediatric Crohn's Disease (MACARONI-23)

TREMFYA (guselkumab)

Pediatric Psoriasis (PROTOSTAR)

nipocalimab

Hemolytic Disease of the Fetus and Newborn (AZALEA)

nipocalimab

Idiopathic Inflammatory Myopathy

nipocalimab Combination Therapy

Rheumatoid Arthritis

JNJ-4804 Co-antibody Therapeutic

Ulcerative Colitis

TREMFYA (guselkumab)

Crohn's Disease (GALAXI)

TREMFYA (guselkumab)

Pediatric Ulcerative Colitis (QUASAR JR)

TREMFYA (guselkumab)

Ulcerative Colitis Subcutaneous Induction (ASTRO)

STELARA (ustekinumab)

Pediatric Ulcerative Colitis (UNIFY JR)

nipocalimab

Warm Autoimmune Hemolytic Anemia (ENERGY)

nipocalimab

Sjogren's Disease

JNJ-4804 Co-antibody Therapeutic

Crohn's Disease

JNJ-2113

Ulcerative Colitis

Immunology (2 of 2)

JNJ-4703

Atopic Dermatitis

JNJ-5939 (NM26)

Atopic Dermatitis

JNJ-4703

Rheumatoid Arthritis

Neuroscience

nipocalimab

Generalized Myasthenia Gravis (Vivacity MG3)

RPGR Gene Therapy

Retinitis Pigmentosa (LUMEOS)

posdinemab

Alzheimer's Disease (AUTONOMY)

JNJ-1887 sCD59

Geographic Atrophy

SPRAVATO (esketamine)

Treatment Resistant Depression monotherapy (TRD4005)

nipocalimab

Chronic Inflammatory Demyelinating Polyneuropathy (ARISE)

nipocalimab

Generalized Myasthenia Gravis Pediatrics (VIBRANCE MG)

M1 Antagonist

Psychiatric Disorder

seltorexant

Adjunctive treatment for major depressive disorder with insomnia symptoms (OARS)

aticaprant

Adjunctive Treatment for Major Depressive Disorder with Anhedonia (Ventura)

SPRAVATO (esketamine)

Major Depressive Disorder with Suicidal Ideation Pediatrics

JNJ-2056 *

Alzheimer's Disease

Select Other Areas

CABENUVA
HIV Adolescents

OPSYNVI (macitentan/tadalafil STCT)
Pulmonary Arterial Hypertension (A DUE)

VAC52416
Multivalent ExPEC Vaccine

milvexian (Factor Xla)
Secondary Stroke Prevention

OPSUMIT (macitentan)
Pediatric Pulmonary Arterial Hypertension
(TOMORROW)

UPTRAVI (selexipag)
Pediatric Pulmonary Arterial Hypertension (SALTO)

milvexian (Factor Xla)
Atrial Fibrillation

SIRTURO
Tuberculosis Long Acting

EDURANT (rilpivirine)
HIV pediatric 2-12 year old

macitentan
Pulmonary Arterial Hypertension 75mg (UNISUS)

milvexian (Factor Xla)
Acute Coronary Syndrome

prostacyclin receptor agonist
Pulmonary Arterial Hypertension

*This information is as of October 15, 2024 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. *AC Immune ACI-35.030. Strategic Partnerships, Collaborations, and Licensing arrangements - XARELTO: Bayer; milvexian: Bristol Myers Squibb; X-Linked Retinitis Pigmentosa (AAV-RPGR): MeiraGTx; JNJ-1887: Hemera Biosciences; COMPLERA / EVIPLERA, ODEFSEY, SYMTUZA, PREZCOBIX / REZOLSTA FDC: Gilead Sciences; JULUCA and Long acting HIV injectable treatment regimen of rilpivirine and cabotegravir: ViiV Healthcare; Cloudbreak antiviral conjugates (AVCs); ExPEC: Sanofi; REMICADE and SIMPONI/SIMPONI ARIA: Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation; TREMFYA: MorphoSys AG; JNJ-2113: Protagonist Therapeutics; Tau Vaccine: AC Immune SA; JNJ-1813: Addex Pharmaceuticals; IMBRUVICA: Pharmacyclics, LLC, an AbbVie company; ZYTIGA: BTG International; VELCADE: Millennium, The Takeda Oncology Company; DARZALEX and DARZALEX FASPRO; Genmab A/S; BALVERSA: Astex Pharmaceuticals; ERLEADA: Regents of California and Memorial Sloan Kettering; CARVYKTI: Legend Biotech; AKEEGA: TESARO, an oncology-focused business within GSK; lazertinib: Yuhan Corporation; Duobody Platform bispecific antibody programs: Genmab A/S; ENHANZE platform; Halozyme Therapeutics; XmAb CD28 bispecific antibodies; Xencor; iPSC-derived chimeric antigen receptor (CAR) NK and CAR T-cell product candidates: Fate Therapeutics; UPTRAVI and OPSUMIT: Nippon Shinyaku (co-promotion in Japan); JNJ-1459: X-CHEM; JNJ-1802: KU Leuven Rega Institute, the KU Leuven Centre for Drug Design and Discovery (CD3), Department of Virology at the Biomedical Primate Research Centre, Department of Infectious Diseases at Heidelberg University, Sealy Institute for Vaccine Sciences at the University of Texas Medical Branch Health (UTMB), Unité des Virus Émergents at Aix-Marseille University and the Walter Reed Army Institute of Research.